Zydus Lifesciences bought back shares at ₹1,260 per share through a tender offer that ran from 4 June 2026 to 10 June 2026 (record date 29 May 2026), with the shares listed on the BSE, NSE. Shareholders on the register on 29 May 2026, the record date, were eligible to tender. The offer covered 87,30,158 shares, 0.87% of the equity, about ₹1,100 crore.
The buyback price was 22.3 percent above the closing price of ₹1,030.01 on 19 May 2026, the last close before the offer; a small shareholder could tender up to 158 shares within the two-lakh-rupee limit. Zydus Lifesciences Ltd. is a leading Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat. Formerly known as Cadila Healthcare, the company discovers, develops, manufactures, and markets a broad range of healthcare therapies, generic drugs, vaccines, and wellness products.
It is India's fourth-largest pharmaceutical company by market capitalization.
| Acceptance | Shares accepted | Profit |
|---|---|---|
| 33% | 52 | ₹11,959 |
| 50% | 79 | ₹18,169 |
| 75% | 118 | ₹27,138 |
| 100% | 158 | ₹36,338 |
Before brokerage and tax, on the maximum small-shareholder holding at the last close before the offer; the offer has since closed.
| Metric | 31-Mar-26 | 31-Mar-25 |
|---|---|---|
| Profit After Tax | 5,040 | 4,525.5 |
| Revenue | 27,657.9 | 23,511 |
| Total Assets | 52,406.6 | 37,201.7 |
In a tender offer the company fixes a price, usually above the market price, and invites every shareholder who held shares on the record date to offer some or all of them back. The entitlement ratio says how many shares you may tender for every share you hold, and because most offers are oversubscribed the acceptance ratio, the share of tendered shares the company actually buys, is known only after the offer closes.
Shares are tendered through your broker during the offer window; accepted shares are paid for at the buyback price and the rest return to your demat account within a few days of the close.
Fifteen percent of every tender offer is reserved for small shareholders, defined as those whose holding in the company was worth two lakh rupees or less at the market price on the record date. Because far fewer shares are tendered in that category, its entitlement ratio is usually much higher than the general category's, and that reservation is the reason retail investors follow buybacks at all.
The figures on this page show how many Zydus Lifesciences shares fit within the limit, what they cost at the last closing price, and what the profit would be at different acceptance ratios, before brokerage and tax.
Since October 2024 the amount a shareholder receives in a buyback is taxed as a dividend in their hands at their slab rate, and the cost of the accepted shares becomes a capital loss that can be set off against capital gains. That makes the after-tax result quite different from the headline premium, and for a shareholder in a high tax bracket a buyback with a modest premium can be worth less than selling on the exchange.
Work it through for your own bracket, or ask a tax adviser, before tendering.
₹1,260 per share, 22.3 percent above the closing price of ₹1,030.01 on 19 May 2026, the last close before the offer. The premium over the market price is what made tendering worthwhile.
29 May 2026. Shareholders had to hold the shares in their demat account on that date, which meant buying them by 28 May 2026 so that delivery settled in time.
The tender window ran from 4 June 2026 to 10 June 2026. Shares were tendered through brokers, and tender forms were accepted until 10 June 2026.
5/49: the company accepted 5 shares for every 49 held, about 10.2 percent of a small shareholder's holding, before any unaccepted shares from other categories were redistributed. The general category ratio was 7/937.
Up to 158 shares, which is the two-lakh-rupee small-shareholder limit divided by the buyback price of ₹1,260. At the closing price of ₹1,030.01 that holding cost about ₹1,62,742.
The offer closed on 10 June 2026. The company has not published the final acceptance ratio; the table shows what the profit would have been at 33 to 100 percent acceptance. At 33 percent the profit on a maximum small-shareholder holding would have been about ₹11,959; at 100 percent about ₹36,338, before brokerage and tax.
Accepted shares were paid for at ₹1,260 and unaccepted shares were returned to demat accounts by 17 June 2026.
For buybacks completed after 1 October 2024 the amount received is taxed as dividend income at your slab rate, and the cost of the accepted shares becomes a capital loss that can be set off against capital gains. Confirm the treatment for your own position with a tax adviser.